Search Results 331-340 of 17564 for vitiligo

1. Blood and Bone Marrow Transplantation Dermatology Clinic

   Watch Mayo Clinic dermatologist Julia Lehman, M.D., describe how specialists work together to help people who develop skin changes following blood and ...

2. A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors - Mayo Clinic

   Patients with Type 1 diabetes, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible. Note: Other ...

3. An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer - Mayo Clinic

   Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not ...

4. Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer - Mayo Clinic

   ... vitiligo or diabetes are not excluded; replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or ...

5. Atezolizumab Immunotherapy in Patients With Advanced NSCLC (AJCC 7th Edition) - Mayo Clinic

   Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would ...

6. Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   Eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only provided all of following are true: Rash covers < 10% of body ...

7. https://www.mayoclinic.org/spanish_patient_consumer_video.xml

8. A Study of Taxane, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Metastatic Breast Cancer Patients - Mayo Clinic

   Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would ...

9. IFX_HU2.0 As An Adjunctive Therapy To Pembrolixumab In Checkpoint Inhibitor Naive Subjects With Advanced Or Metastatic Merkel Cell Carcinoma - Mayo Clinic

   ... vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll. Low grade autoimmune toxicity is NOT an exclusion under this ...

10. A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab - Mayo Clinic

    However, patients with diabetes type 1, vitiligo, psoriasis, or hypo- or hyper-thyroid disease not requiring immunosuppressive treatment are eligible. Acute ...